Daily Anesthesiology Research Analysis
Analyzed 42 papers and selected 3 impactful papers.
Summary
Today's top anesthesiology-adjacent advances span mechanistic transplantation science, perioperative neuromodulation, and pediatric premedication. A Cell study identifies ferroptosis as a tractable target to protect liver and lung grafts, a randomized trial shows auricular vagus nerve stimulation reduces postoperative cognitive dysfunction in older adults, and a meta-analysis supports intranasal dexmedetomidine over intranasal midazolam for pediatric preoperative anxiety.
Research Themes
- Ischemia-reperfusion injury mitigation and organ preservation
- Perioperative neuromodulation to prevent cognitive complications
- Pediatric premedication optimization and anxiolysis
Selected Articles
1. Ferroptosis inhibition enhances liver and lung graft function.
This translational study identifies early lipid peroxidation as a therapeutic target in human liver transplants and demonstrates that ferroptosis inhibition (FXT-001) preserves graft viability in porcine liver/lung perfusion and split ex vivo perfusion of declined human lungs. Next-generation inhibitors (FXT-002/003) showed improved pharmacokinetics and safety profiles, supporting ferroptosis blockade as a strategy against ischemia-reperfusion injury.
Impact: It provides mechanistic and translational evidence that targeting ferroptosis can protect grafts during preservation, a potential paradigm shift for organ transplantation and perioperative organ protection.
Clinical Implications: If validated clinically, ferroptosis inhibitors could be incorporated into ex situ machine perfusion protocols to improve graft quality and expand the donor pool, with potential applications across IRI-associated surgeries.
Key Findings
- Early, transient lipid peroxidation increases were identified in human liver transplants, validating a therapeutic target.
- FXT-001 preserved graft viability in ex situ perfusion of porcine liver and lung grafts.
- In split ex vivo perfusion of declined human donor lungs, FXT-001 preserved viability whereas untreated lungs deteriorated.
- Next-generation ferroptosis inhibitors (FXT-002/FXT-003) with improved pharmacokinetics and safety were developed.
Methodological Strengths
- Multi-system translational approach spanning human transplant samples, large-animal ex situ perfusion, and human declined donor tissues
- Mechanism-driven target validation with drug candidates optimized for PK and safety
Limitations
- Preclinical and ex vivo nature limits immediate generalizability to clinical outcomes
- Sample sizes and long-term post-transplant outcomes are not reported
- Regulatory and safety data in humans remain to be established
Future Directions: Conduct first-in-human trials integrating ferroptosis inhibitors into organ machine perfusion, define dosing/exposure-response, and assess graft function and recipient outcomes across transplant types and other IRI contexts.
Ischemia-reperfusion injury (IRI) is a major clinical challenge in transplantation, vascular surgeries, myocardial infarction, and stroke. Disruption of energy and redox homeostasis triggers ferroptosis, a regulated, iron-dependent form of cell death, leading to organ dysfunction. We identify an early and transient increase of lipid peroxidation in human liver transplants and validate it as a therapeutic target. FXT-001, a ferroptosis inhibitor with dual radical and iron-trapping activity, provides robust protection in preclinical models, including ex situ perfusion of porcine liver and lung grafts. In a split ex vivo machine perfusion setting using declined human donors, FXT-001 treatment preserves graft viability, whereas untreated lungs deteriorate. We also develop FXT-002 and FXT-003 with enhanced pharmacokinetic and safety profiles. These findings support the use of ferroptosis inhibitors as a therapeutic strategy in transplantation and other IRI-associated conditions.
2. Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Postoperative Cognitive Dysfunction in Older Patients: A Randomized Controlled Clinical Trial.
In 103 older adults undergoing gastrointestinal tumor surgery, daily perioperative taVNS reduced early POCD compared with sham stimulation. The protocol used brief 30-minute sessions preoperatively and on postoperative days 1–4, with cognitive outcomes assessed by MoCA through postoperative day 7; anti-inflammatory mechanisms are suggested.
Impact: This RCT introduces a low-risk, scalable neuromodulation strategy to prevent POCD, a prevalent and consequential perioperative complication in the elderly.
Clinical Implications: taVNS could be integrated as a nonpharmacologic adjunct to reduce POCD risk in older surgical patients, pending confirmation in multicenter trials and longer-term cognitive follow-up.
Key Findings
- Randomized, sham-controlled trial of 103 older adults undergoing gastrointestinal tumor surgery.
- taVNS administered preoperatively and POD1–4 (30 minutes/session) reduced early POCD incidence versus sham (10.2% vs 32.7%).
- Cognitive outcomes were assessed with MoCA through POD7; inflammatory biomarkers (S100β, IL-6) and other postoperative outcomes were measured as secondary endpoints.
Methodological Strengths
- Randomized, sham-controlled design with standardized cognitive assessment (MoCA)
- Defined, reproducible stimulation protocol with perioperative timing
Limitations
- Single-center study with modest sample size and short follow-up (to POD7)
- Retrospective trial registration and potential limited blinding integrity
Future Directions: Conduct multicenter RCTs with longer cognitive follow-up, define dose–response and optimal timing, and evaluate integration with multimodal POCD prevention bundles.
OBJECTIVES: The aim of this study was to investigate the effect of transauricular vagus nerve stimulation (taVNS) on early postoperative cognitive dysfunction (POCD) in older patients and further explore the mechanism by which vagus nerve stimulation improves postoperative cognitive function.
MATERIALS AND METHODS: A total of 103 patients undergoing elective surgery for gastrointestinal tumors were selected and randomly assigned to the taVNS group (n = 49) or the sham taVNS (sham) group (n = 52), receiving auricular vagal nerve stimulation or sham stimulation therapy (once daily for 30 minutes, 4/20 Hz, 0.8-1.5 mA or 0 mA) on preoperative day 1 and on postoperative day (POD) 1, POD2, POD3, and POD4. The primary outcome was the cognitive function assessed by Montreal Cognitive Assessment on preoperative day 1 and on POD1, POD3, and POD7. The secondary study indicators were postoperative nausea and vomiting (PONV), postoperative delirium, postoperative sleep quality, perioperative changes in S100 calcium binding protein beta (S100β) and interleukin 6 (IL-6), and postoperative pain intensity.
RESULTS: The incidence of POCD in the taVNS group was significantly lower than that in the sham group (10.2% vs 32.7%, χ
CONCLUSIONS: taVNS can reduce the incidence of POCD in older patients and may improve cognitive function by suppressing the inflammatory response.
CLINICAL TRIAL REGISTRATION: The clinical trial registration number for the study is ChiCTR2500115495 (Chinese Clinical Trial Register, December 26, 2025-retrospectively registered; https://www.chictr.org.cn/bin/project/edit?pid=292929).
3. Comparative safety and sedation effectiveness of intranasal dexmedetomidine versus midazolam for preoperative anxiety reduction in pediatric surgical patients: an updated systematic review and meta-analysis.
Across 19 RCTs (n=1475), intranasal dexmedetomidine reduced pediatric preoperative anxiety and parental separation anxiety versus intranasal midazolam and lowered heart rate. Compared with oral midazolam, differences were not statistically significant, likely due to limited power.
Impact: This updated meta-analysis informs medication choice for pediatric premedication by synthesizing head-to-head evidence between common regimens.
Clinical Implications: Intranasal dexmedetomidine can be favored over intranasal midazolam for pediatric preoperative anxiolysis; equivalence with oral midazolam remains uncertain and warrants individualized selection.
Key Findings
- Included 19 RCTs with 1,475 pediatric patients; PROSPERO-registered protocol.
- Intranasal dexmedetomidine vs intranasal midazolam: lower anxiety at/before induction (SMD -1.10), lower parental separation anxiety (SMD -0.56), and lower mean heart rate (MD -6.60 bpm).
- Intranasal dexmedetomidine vs oral midazolam: no significant differences in anxiety, parental separation anxiety, or emergence agitation; potential underpowering.
Methodological Strengths
- Focus on randomized controlled trials with head-to-head comparisons
- Comprehensive multi-database search and quantitative synthesis
Limitations
- Heterogeneity in dosing, scales, and timing across trials
- English-language restriction and potential underpower for comparisons with oral midazolam
Future Directions: Design adequately powered RCTs directly comparing intranasal dexmedetomidine with oral midazolam using standardized dosing and outcome measures, including safety endpoints.
BACKGROUND: Relieving pre-operative anxiety in children is a major concern for anesthesiologists. Midazolam has been the most commonly used sedative agent due to its long history of efficacy. However, it has been associated with complications, such as agitation, cognitive impairment, amnesia, and respiratory depression. For these reasons, other drugs, such as dexmedetomidine, have been explored as safe and effective alternatives in children undergoing surgery.
OBJECTIVE: To evaluate the efficacy and safety of intranasal dexmedetomidine as compared to intranasal or oral midazolam in reducing preoperative anxiety in pediatric surgical patients.
METHODS: PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched for relevant articles published from inception to January 2026. The search was limited to articles written in English and involved keywords and MeSH terms related to midazolam, dexmedetomidine, surgery, and children.
RESULTS: Nineteen randomized controlled trials with 1475 pediatric surgical patients were included. The pooled analysis revealed that intranasal dexmedetomidine was associated with significantly lower anxiety scores at or before induction (SMD: -1.10; 95% CI: -1.68 to -0.53; p = 0.0002), parental separation anxiety (SMD: -0.56; 95% CI: -0.99 to -0.12; p = 0.01), and mean heart rate (HR) (MD: -6.60 beats/min; 95% CI: -10.56 to -2.64; p = 0.001) compared to intranasal midazolam. However, intranasal dexmedetomidine was comparable to oral midazolam in terms of anxiety at or before induction (MD: -7.70; 95% CI: -18.89 to 3.59; p = 0.18), parental separation anxiety (RR: 1.13; 95% CI: 0.44 to 2.88; p = 0.80), and postoperative emergence agitation (RR: 0.22; 95% CI: 0.02 to 2.94; p = 0.25).
CONCLUSION: Intranasal dexmedetomidine is more effective than intranasal midazolam in reducing preoperative anxiety in children. No statistically significant difference was detected between intranasal dexmedetomidine and oral midazolam, but studies may have been underpowered to detect clinically important differences.
SYSTEMATIC REVIEW PROTOCOL REGISTRATION: PROSPERO: CRD420251234972.